Annual CFO
-$23.38 M
+$49.77 M+68.03%
31 December 2023
Summary:
Akebia Therapeutics annual cash flow from operations is currently -$23.38 million, with the most recent change of +$49.77 million (+68.03%) on 31 December 2023. During the last 3 years, it has risen by +$87.00 million (+78.82%). AKBA annual CFO is now -140.38% below its all-time high of $57.91 million, reached on 31 December 2016.AKBA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$6.70 M
+$3.37 M+33.49%
30 September 2024
Summary:
Akebia Therapeutics quarterly cash flow from operations is currently -$6.70 million, with the most recent change of +$3.37 million (+33.49%) on 30 September 2024. Over the past year, it has increased by +$472.00 thousand (+6.59%). AKBA quarterly CFO is now -107.00% below its all-time high of $95.67 million, reached on 31 December 2016.AKBA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$38.50 M
+$472.00 K+1.21%
30 September 2024
Summary:
Akebia Therapeutics TTM cash flow from operations is currently -$38.50 million, with the most recent change of +$472.00 thousand (+1.21%) on 30 September 2024. Over the past year, it has increased by +$37.25 million (+49.18%). AKBA TTM CFO is now -146.80% below its all-time high of $82.26 million, reached on 30 June 2017.AKBA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AKBA Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +68.0% | +6.6% | +49.2% |
| 3 y3 years | +78.8% | +88.1% | +82.6% |
| 5 y5 years | +76.0% | -160.9% | +83.9% |
AKBA Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +90.8% | -119.8% | +89.3% | -64.7% | +84.8% |
| 5 y | 5 years | at high | +90.9% | -118.0% | +92.7% | -64.7% | +85.0% |
| alltime | all time | -140.4% | +90.9% | -107.0% | +95.2% | -146.8% | +85.3% |
Akebia Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$6.70 M(-33.5%) | -$38.50 M(-1.2%) |
| June 2024 | - | -$10.07 M(-48.2%) | -$38.97 M(+54.2%) |
| Mar 2024 | - | -$19.43 M(+741.9%) | -$25.28 M(+8.1%) |
| Dec 2023 | -$23.38 M(-68.0%) | -$2.31 M(-67.8%) | -$23.38 M(-69.1%) |
| Sept 2023 | - | -$7.17 M(-297.5%) | -$75.75 M(+117.8%) |
| June 2023 | - | $3.63 M(-120.7%) | -$34.78 M(-49.6%) |
| Mar 2023 | - | -$17.54 M(-67.9%) | -$69.07 M(-5.6%) |
| Dec 2022 | -$73.15 M(-71.1%) | -$54.68 M(-261.7%) | -$73.15 M(-10.0%) |
| Sept 2022 | - | $33.80 M(-210.3%) | -$81.28 M(-52.6%) |
| June 2022 | - | -$30.66 M(+41.8%) | -$171.36 M(-15.9%) |
| Mar 2022 | - | -$21.62 M(-65.6%) | -$203.84 M(-19.4%) |
| Dec 2021 | -$252.97 M(+129.2%) | -$62.81 M(+11.6%) | -$252.97 M(+14.5%) |
| Sept 2021 | - | -$56.27 M(-10.9%) | -$220.94 M(+15.1%) |
| June 2021 | - | -$63.14 M(-10.7%) | -$191.91 M(+109.6%) |
| Mar 2021 | - | -$70.75 M(+129.8%) | -$91.55 M(-17.1%) |
| Dec 2020 | -$110.39 M(-57.1%) | -$30.78 M(+13.0%) | -$110.39 M(-35.7%) |
| Sept 2020 | - | -$27.24 M(-173.2%) | -$171.74 M(+28.6%) |
| June 2020 | - | $37.22 M(-141.5%) | -$133.51 M(-36.1%) |
| Mar 2020 | - | -$89.59 M(-2.8%) | -$209.10 M(-18.8%) |
| Dec 2019 | -$257.44 M(+164.1%) | -$92.14 M(-938.4%) | -$257.44 M(+7.7%) |
| Sept 2019 | - | $10.99 M(-128.6%) | -$239.00 M(-8.9%) |
| June 2019 | - | -$38.37 M(-72.2%) | -$262.45 M(+22.0%) |
| Mar 2019 | - | -$137.93 M(+87.2%) | -$215.09 M(+120.6%) |
| Dec 2018 | -$97.49 M | -$73.70 M(+491.4%) | -$97.49 M(+142.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$12.46 M(-238.5%) | -$40.17 M(-51.2%) |
| June 2018 | - | $9.00 M(-144.2%) | -$82.33 M(+23.0%) |
| Mar 2018 | - | -$20.33 M(+24.1%) | -$66.96 M(+19.2%) |
| Dec 2017 | -$56.16 M(-197.0%) | -$16.38 M(-70.0%) | -$56.16 M(-200.5%) |
| Sept 2017 | - | -$54.62 M(-324.2%) | $55.89 M(-32.1%) |
| June 2017 | - | $24.36 M(-355.7%) | $82.26 M(+165.8%) |
| Mar 2017 | - | -$9.53 M(-110.0%) | $30.94 M(-46.6%) |
| Dec 2016 | $57.91 M(-210.5%) | $95.67 M(-438.7%) | $57.91 M(-195.4%) |
| Sept 2016 | - | -$28.24 M(+4.8%) | -$60.68 M(+46.3%) |
| June 2016 | - | -$26.95 M(-254.6%) | -$41.46 M(+55.7%) |
| Mar 2016 | - | $17.43 M(-176.1%) | -$26.63 M(-49.2%) |
| Dec 2015 | -$52.41 M(+90.7%) | -$22.91 M(+153.7%) | -$52.41 M(+35.4%) |
| Sept 2015 | - | -$9.03 M(-25.5%) | -$38.70 M(+9.7%) |
| June 2015 | - | -$12.12 M(+45.2%) | -$35.27 M(+18.3%) |
| Mar 2015 | - | -$8.35 M(-9.3%) | -$29.82 M(+8.5%) |
| Dec 2014 | -$27.48 M(+142.5%) | -$9.20 M(+64.3%) | -$27.48 M(+18.5%) |
| Sept 2014 | - | -$5.60 M(-16.0%) | -$23.19 M(+13.0%) |
| June 2014 | - | -$6.67 M(+11.0%) | -$20.52 M(+29.8%) |
| Mar 2014 | - | -$6.01 M(+22.4%) | -$15.81 M(+39.5%) |
| Dec 2013 | -$11.33 M(+57.1%) | -$4.91 M(+67.1%) | -$11.33 M(+76.4%) |
| Sept 2013 | - | -$2.94 M(+50.1%) | -$6.42 M(+84.3%) |
| June 2013 | - | -$1.96 M(+27.9%) | -$3.49 M(+127.9%) |
| Mar 2013 | - | -$1.53 M | -$1.53 M |
| Dec 2012 | -$7.21 M | - | - |
FAQ
- What is Akebia Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Akebia Therapeutics?
- What is Akebia Therapeutics annual CFO year-on-year change?
- What is Akebia Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Akebia Therapeutics?
- What is Akebia Therapeutics quarterly CFO year-on-year change?
- What is Akebia Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Akebia Therapeutics?
- What is Akebia Therapeutics TTM CFO year-on-year change?
What is Akebia Therapeutics annual cash flow from operations?
The current annual CFO of AKBA is -$23.38 M
What is the all time high annual CFO for Akebia Therapeutics?
Akebia Therapeutics all-time high annual cash flow from operations is $57.91 M
What is Akebia Therapeutics annual CFO year-on-year change?
Over the past year, AKBA annual cash flow from operations has changed by +$49.77 M (+68.03%)
What is Akebia Therapeutics quarterly cash flow from operations?
The current quarterly CFO of AKBA is -$6.70 M
What is the all time high quarterly CFO for Akebia Therapeutics?
Akebia Therapeutics all-time high quarterly cash flow from operations is $95.67 M
What is Akebia Therapeutics quarterly CFO year-on-year change?
Over the past year, AKBA quarterly cash flow from operations has changed by +$472.00 K (+6.59%)
What is Akebia Therapeutics TTM cash flow from operations?
The current TTM CFO of AKBA is -$38.50 M
What is the all time high TTM CFO for Akebia Therapeutics?
Akebia Therapeutics all-time high TTM cash flow from operations is $82.26 M
What is Akebia Therapeutics TTM CFO year-on-year change?
Over the past year, AKBA TTM cash flow from operations has changed by +$37.25 M (+49.18%)